
GSK vs PHAR
$GSK vs $PHAR head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
GSK vs PHAR: trend, levels and the market
One year to 2026-11-18, against the S&P 500 (+10.2%). Split-adjusted daily closes.
- ·GSK is the weaker of the two on trend, below both its 50- and 200-day averages, while PHAR has held above one of them.
- ·Neither kept up with the market over the past year: GSK +4.8% and PHAR -22.5%, against the S&P 500 at +10.2%.
- ·The last month has flipped the order: PHAR leads over the month (+28% against -4%) even though GSK leads over the year.
- ·PHAR has support 6% below at $11.73; GSK has no tested support within 35% under its price.
- ·GSK is within 2.2% of resistance at $49.63, a price where it has stalled before.
Support and resistance are daily prices the stock has turned at three or more times, within 35% of the price. The loading zone is the nearby price where the heaviest volume traded. These describe where a stock has been, not where it will go. Not investment advice.
GSK vs PHAR: the quick read
- ·GSK is the larger company by market cap ($98.26B vs $884M).
- ·GSK has been more active on our scanner (69 vs 4 alerts in 30 days).
- ·PHAR has the smaller float (70.8M vs 2.00B), which tends to mean sharper, more volatile moves.
- ·Both are pharmaceutical preparations names, so this is a like-for-like comparison and sector news tends to move them together.
- ·GSK draws far more of our scanner's attention, 69 unusual-volume alerts in 30 days against 4, so it is the more actively traded of the two by some distance.
- ·They are not really peers by size: GSK is more than 111x the market cap of PHAR, so the same dollar of news moves PHAR far harder.
- ·GSK pays a dividend and PHAR does not, which usually means one is being held for income and the other for the move.
Objective differences only. Not investment advice.
Watching GSK or PHAR? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing GSK and PHAR on TheDesperateTrader.
- Is GSK or PHAR the better stock?
- "Better" depends on your goal, and these two are not alike. GSK is the larger company by market cap ($98.26B vs $884M). GSK has been more active on our scanner (69 vs 4 alerts in 30 days). PHAR has the smaller float (70.8M vs 2.00B), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between GSK and PHAR?
- The differences that matter: GSK is roughly 111x the size of the other by market cap ($98.26B vs $884M); they trade at very different share prices ($48.58 vs $12.48); GSK sits at 17% of its 52-week range against 28% for PHAR; only GSK pays a dividend; our scanner flagged GSK 69 times in the last 30 days against 4 for PHAR. Everything above is measured from the latest completed session and SEC filings.
- Which of GSK and PHAR is more active right now?
- Right now GSK is at about 0.5x its normal volume and PHAR is at about 0.4x, so GSK is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is GSK or PHAR in the stronger trend?
- GSK is below its 50-day average of $49.32 and below its 200-day average of $52.36; PHAR is above its 50-day average of $11.03 and below its 200-day average of $13.36. PHAR leads 3 of the 5 measures on this page (1 year, vs S&P 500, 3 months, 1 month, trend). A trend is where a stock has been, not a forecast, and nothing here is investment advice.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading GSK or PHAR? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysExplore the market
Free, live market tools. No account required to look.